Esaxerenone Combined With RAAS Inhibitor Dramatically Reduces Nighttime Blood Pressure and NT-proBNP | Research

The takeaway

Esaxerenone combined with a renin-angiotensin system inhibitor reduced nighttime systolic blood pressure by 20.6 mmHg and significantly decreased NT-proBNP (a peptide biomarker of cardiovascular risk) in patients with uncontrolled hypertension.

-20.6 mmHg nighttime SBP with RASi combination
Dual RAAS/aldosterone blockade produced the largest nocturnal blood pressure reduction and significant NT-proBNP decreases across all groups

What the researchers found

Among 270 patients with uncontrolled hypertension, esaxerenone treatment produced significant nocturnal blood pressure reductions across all groups:

- Monotherapy (n=172): 24h SBP -10.0 mmHg

- With calcium channel blocker (n=49): 24h SBP -6.0 mmHg

- With RAAS inhibitor (n=49): 24h SBP -17.0 mmHg

Nighttime systolic BP decreased significantly (P < 0.001) in all groups by week 28, with the RAAS inhibitor combination showing the greatest effect (-20.6 mmHg nighttime SBP). NT-proBNP (N-terminal pro-B-type natriuretic peptide), a peptide biomarker of cardiovascular prognosis, decreased significantly in all three treatment groups.

Why it matters

Nocturnal hypertension is particularly dangerous because it indicates the cardiovascular system isn't getting adequate rest during sleep. The combination of esaxerenone with a renin-angiotensin system inhibitor targets two key peptide-mediated pathways: aldosterone (mineralocorticoid) and angiotensin. The significant reduction in NT-proBNP — a natriuretic peptide fragment that rises with cardiac stress — suggests this combination not only lowers pressure but actually reduces the cardiovascular burden, which may translate to fewer heart failure events.

How the study worked

Post hoc analysis of a multicenter, open-label, phase 3 study in Japanese patients with uncontrolled hypertension. 270 patients were analyzed across three groups: esaxerenone monotherapy (n=172), esaxerenone + calcium channel blocker (n=49), and esaxerenone + RAS inhibitor (n=49). 24-hour ambulatory blood pressure monitoring assessed nighttime and daytime BP at baseline and week 28. NT-proBNP levels were measured as a cardiovascular biomarker endpoint.

What this study cannot tell us

This is a post hoc analysis of an open-label (non-blinded) trial, which is methodologically weaker than a pre-planned blinded analysis. The study was conducted exclusively in Japanese patients, and blood pressure responses may differ in other populations. Sample sizes in the combination groups were small (49 each). The study lacked a placebo control group. The 28-week duration may not capture long-term cardiovascular outcome benefits.

How to read the evidence

This is a post hoc analysis of a phase 3 open-label study — intermediate evidence quality. The significant blood pressure and NT-proBNP reductions are clinically meaningful, but the post hoc design, lack of blinding, and small combination therapy subgroups limit the strength of conclusions.

When this study was published

Published in 2025, this is a recent analysis providing current data on esaxerenone combination therapy, a newer mineralocorticoid receptor antagonist that offers advantages over older agents like spironolactone.

The bigger picture

The renin-angiotensin-aldosterone system (RAAS) is one of the body's primary peptide hormone systems for blood pressure regulation. This study demonstrates the power of dual RAAS blockade — combining an angiotensin pathway inhibitor with an aldosterone pathway blocker — for controlling the most dangerous form of hypertension (nocturnal). The NT-proBNP reductions add a peptide biomarker dimension, suggesting these blood pressure improvements translate to reduced cardiac stress at the molecular level.

Questions still open

Does the nocturnal blood pressure reduction with esaxerenone + RASi translate to reduced cardiovascular events in outcome trials?
Would this combination be similarly effective in non-Asian populations with resistant hypertension?
Can NT-proBNP changes during esaxerenone therapy predict which patients will benefit most?

Common questions

Why is nighttime blood pressure more dangerous than daytime?

Blood pressure normally drops 10-20% during sleep (called 'dipping'). When this doesn't happen (non-dipping) or pressure actually rises at night, it puts continuous stress on the heart, blood vessels, kidneys, and brain. Research shows that nighttime blood pressure is a stronger predictor of heart attacks, strokes, and death than daytime readings, making it an important target for treatment.

What is NT-proBNP and why does it matter in this study?

NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a fragment of a peptide hormone released by the heart when it's under stress. Higher levels indicate the heart is working too hard. The fact that esaxerenone treatment lowered NT-proBNP suggests it's not just reducing blood pressure numbers — it's actually reducing the strain on the heart, which may translate to fewer heart failure events and better long-term cardiovascular outcomes.

Read the original research

Efficacy of Esaxerenone Plus a Renin-Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis.

American journal of hypertension, 38(8), 605-611

View on PubMed ↗Publisher’s paper ↗

Citation

Kario, Kazuomi; Ito, Sadayoshi; Itoh, Hiroshi; Rakugi, Hiromi; Okuda, Yasuyuki; Yamakawa, Satoru. (2025). Efficacy of Esaxerenone Plus a Renin-Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis.. American journal of hypertension, 38(8), 605-611. https://doi.org/10.1093/ajh/hpaf048